SPY отыграл гэп вниз на премаркете

Ближайший уровень поддержки по SPY – 194.25 уровень сопротивления – 195.00



MASI смотрим на продажу с открытия

EDZ покупка выше 37

GTLS покупка выше 53

Gapping up/down: GPN +5% after earnings, WLT +6% on M&A spec, DTV +1.5% after renewed Sunday Ticket deal, TWTR +2% on upgrade at JPM; CREE -13% and AGU -5.5% after earnings/guidance, JPM -1% after dg at UBS Price: null Change: null 

Gapping up 
In reaction to strong earnings/guidance: GPN +5.4%, DRI +0.8%

M&A news: WLT +5.8% (may be an acquisition target by BHP (BHP), according to reports)

Select semiconductor stocks trading higher: UMC +2%, STM +1.6%, MU +1.4%, ASML +1.4%, AMD +1.2%

Other news: ESPR +33.4% (announces positive top-line Phase 2b results for ETC-1002, an investigational therapy for patients with hypercholesterolemia ), RLD +21.9% (Starboard raises stake to 9.9% and delivered a letter to the Board proposing to acquire the company for $12 per share), ARIA +10.2% (announces AP26113 has received Breakthrough Therapy designation by the FDA), LEU +8.8% (elects Williams as Chairman; begins process for CEO Transition; Chief Restructuring Officer John Castellano named interim CEO; John Welch to step down later this month), BTU +7% (WLT peer, may be in sympathy), DRL +6.2% (provided an update on status of its capital plan: co maintains readily available liquidity sources of ~$1 bln), SPEX +5.4% (cont momentum), GRMN +5% (announces Honda (HMC) has selected Garmin as the navigation provider for future Civic and CR-V models in Europe, Russia and South America), NBG +3.8% (still checking), TSLA +3.6% (Elon Musk tweets 'About time to unveil the D and something else'; suggesting Model D introduction on Oct 9), DTV +1.4% (Co and NFL extended and expanded DIRECTV's exclusive rights to carry NFL SUNDAY TICKET), ARG +1.3% (to increase argon prices by up to 15%, effective November 1 or as contracts permit), QIHU +1.1% (announces $200 mln Share Repurchase Plan), TKMR +1% (ebola play that was +18% yesterday)


Analyst comments: NDAQ +4.4% (upgraded to Buy from Hold at Deutsche Bank), ADSK +3.3% (upgraded to Outperform from Mkt Perform at Cowen), AKS +2.9% (upgraded to Buy from Hold at Deutsche Bank), TWTR +2.3% (upgraded to Overweight from Neutral at JP Morgan), JBLU +2% (upgraded to Mkt Perform from Underperform at Raymond James), RUBI +1.6% (initiated with a Buy at B. Riley & Co), P +1.5% (upgraded to Buy at Topeka Capital Markets), THRM +0.9% (upgraded to Outperform from Mkt Perform at Barrington Research ), ICE +0.7% (upgraded to Buy from Hold at Deutsche Bank), EXXI +0.7% (upgraded to Buy from Neutral at Guggenheim), BMS +0.7% (upgraded to Neutral from Underperform at BofA/Merrill), HBI +0.6% (initiated with a Outperform at Credit Suisse), VLO +0.5% (initiated with a Outperform at RBC Capital Mkts), BAC +0.5% (upgraded to Buy from Neutral at UBS)

Gapping down
In reaction to disappointing earnings/guidance: CREE -12.9%, AGU -5.5%, STZ -2.9%

Other news: WILN -13.1% (commenced litigation against several companies), TWI -8.7% (light volume, may be attributed to AGU outlook), NLNK -5.7% (announced appointment of Jack Henneman as Chief Financial Officer following departure of Gordon H. Link, Jr.), DNDN -5.2% (still checking), PTLA -3.6% (Portola Pharma files for 10 mln share common stock shelf offering; commenced an underwritten public offering of shares of its common stock and expects to raise gross proceeds of approximately $160,000,000), GPRO -2.5% (cont pre-mkt vol activity), RDUS -1.7% (announces proposed public offering), RVNC -1.5% (announced expected delay in results from Phase 3 study of RT001 for the treatment of lateral canthal (crow's feet) lines), MRD -1.5% (filed for ~27.8 mln share common stock offering by selling shareholders), POT -1% (following AGU earnings)

Analyst comments: DNDN -5.2% (target cut to $1 from $2 at Citi), ENPH -2.4% (downgraded to Neutral from Buy at BofA/Merrill), JPM -1% (downgraded to Neutral from Buy at UBS), MSI -0.7% (downgraded to Neutral from Buy at Citigroup), X -0.5% (downgraded to Hold from Buy at KeyBanc Capital Mkts), ETN -0.5% (downgraded to Perform from Outperform at Oppenheimer)

Оригинал статьи: gtstocks.com/analytics-02-10-2014.html